EF-hand proteins are ubiquitous in cell signaling. Parvalbumin (Parv), the archetypal EF-hand protein, is a high-affinity Ca2+ buffer in many biological systems. Given the centrality of Ca2+ signaling in health and disease, EF-hand motifs designed to have new biological activities may have widespread utility. Here, an EF-hand motif substitution that had been presumed to destroy EF-hand function, that of glutamine for glutamate at position 12 of the second cation binding loop domain of Parv (ParvE101Q), markedly inverted relative cation affinities: Mg2+ affinity increased, whereas Ca2+ affinity decreased, forming a new ultra-delayed Ca2+ buffer with favorable properties for promoting cardiac relaxation. In therapeutic testing, expression of ParvE101Q fully reversed the severe myocyte intrinsic contractile defect inherent to expression of native Parv and corrected abnormal myocardial relaxation in diastolic dysfunction disease models in vitro and in vivo. Strategic design of new EF-hand motif domains to modulate intracellular Ca2+ signaling could benefit many biological systems with abnormal Ca2+ handling, including the diseased heart.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Nature Communications Open Access 08 June 2022
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Clapham, D.E. Calcium signaling. Cell 131, 1047–1058 (2007).
Bers, D.M. Cardiac excitation-contraction coupling. Nature 415, 198–205 (2002).
Kaye, D.M., Hoshijima, M. & Chien, K.R. Reversing advanced heart failure by targeting Ca2+ cycling. Annu. Rev. Med. 59, 13–28 (2008).
Kass, D.A., Bronzwaer, J.G. & Paulus, W.J. What mechanisms underlie diastolic dysfunction in heart failure? Circ. Res. 94, 1533–1542 (2004).
Yano, M., Ikeda, Y. & Matsuzaki, M. Altered intracellular Ca2+ handling in heart failure. J. Clin. Invest. 115, 556–564 (2005).
MacLennan, D.H. & Kranias, E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566–577 (2003).
Periasamy, M. & Janssen, P.M. Molecular basis of diastolic dysfunction. Heart Fail. Clin. 4, 13–21 (2008).
Zile, M.R., Baicu, C.F. & Gaasch, W.H. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N. Engl. J. Med. 350, 1953–1959 (2004).
Minamisawa, S. et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313–322 (1999).
Jessup, M. et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304–313 (2011).
Kho, C. et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477, 601–605 (2011).
Wang, W. & Metzger, J.M. Parvalbumin isoforms for enhancing cardiac diastolic function. Cell Biochem. Biophys. 51, 1–8 (2008).
Gifford, J.L., Walsh, M.P. & Vogel, H.J. Structures and metal-ion–binding properties of the Ca2+-binding helix-loop-helix EF-hand motifs. Biochem. J. 405, 199–221 (2007).
Heizmann, C.W. Parvalbumin, an intracellular calcium-binding protein; distribution, properties and possible roles in mammalian cells. Experientia 40, 910–921 (1984).
Kretsinger, R.H. & Nockolds, C.E. Carp muscle calcium-binding protein. II. Structure determination and general description. J. Biol. Chem. 248, 3313–3326 (1973).
Pauls, T.L., Cox, J.A. & Berchtold, M.W. The Ca2+-binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Biochim. Biophys. Acta 1306, 39–54 (1996).
Falke, J.J., Drake, S.K., Hazard, A.L. & Peersen, O.B. Molecular tuning of ion binding to calcium signaling proteins. Q. Rev. Biophys. 27, 219–290 (1994).
Strynadka, N.C. & James, M.N. Crystal structures of the helix-loop-helix calcium-binding proteins. Annu. Rev. Biochem. 58, 951–998 (1989).
Declercq, J.P., Tinant, B., Parello, J. & Rambaud, J. Ionic interactions with parvalbumins. Crystal structure determination of pike 4.10 parvalbumin in four different ionic environments. J. Mol. Biol. 220, 1017–1039 (1991).
Babu, A., Su, H., Ryu, Y. & Gulati, J. Determination of residue specificity in the EF-hand of troponin C for Ca2+ coordination, by genetic engineering. J. Biol. Chem. 267, 15469–15474 (1992).
Maune, J.F., Klee, C.B. & Beckingham, K. Ca2+ binding and conformational change in two series of point mutations to the individual Ca2+-binding sites of calmodulin. J. Biol. Chem. 267, 5286–5295 (1992).
Rome, L.C. Design and function of superfast muscles: new insights into the physiology of skeletal muscle. Annu. Rev. Physiol. 68, 193–221 (2006).
Hirsch, J.C. et al. Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 286, H2314–H2321 (2004).
Coutu, P. & Metzger, J.M. Optimal range for parvalbumin as relaxing agent in adult cardiac myocytes: gene transfer and mathematical modeling. Biophys. J. 82, 2565–2579 (2002).
Coutu, P., Bennett, C.N., Favre, E.G., Day, S.M. & Metzger, J.M. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked α-tropomyosin mutations. Circ. Res. 94, 1235–1241 (2004).
Wahr, P.A., Michele, D.E. & Metzger, J.M. Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc. Natl. Acad. Sci. USA 96, 11982–11985 (1999).
Day, S.M. et al. Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering action. Physiol. Genomics 33, 312–322 (2008).
Johnson, J.D., Jiang, Y. & Rall, J.A. Intracellular EDTA mimics parvalbumin in the promotion of skeletal muscle relaxation. Biophys. J. 76, 1514–1522 (1999).
Putkey, J.A., Sweeney, H.L. & Campbell, S.T. Site-directed mutation of the trigger calcium-binding sites in cardiac troponin C. J. Biol. Chem. 264, 12370–12378 (1989).
Negele, J.C., Dotson, D.G., Liu, W., Sweeney, H.L. & Putkey, J.A. Mutation of the high affinity calcium binding sites in cardiac troponin C. J. Biol. Chem. 267, 825–831 (1992).
Yang, J.J., Gawthrop, A. & Ye, Y. Obtaining site-specific calcium-binding affinities of calmodulin. Protein Pept. Lett. 10, 331–345 (2003).
Cates, M.S. et al. Metal-ion affinity and specificity in EF-hand proteins: coordination geometry and domain plasticity in parvalbumin. Structure 7, 1269–1278 (1999).
Hutnik, C.M., MacManus, J., Banville, D. & Szabo, A. Comparison of metal ion-induced conformational changes in parvalbumin and oncomodulin as probed by the intrinsic fluorescence of tryptophan 102. J. Biol. Chem. 265, 11456–11464 (1990).
Schwartz, A. Methods in Pharmacology: Myocardial Biology Vol. 5, 63–75 (Plenum Press, New York, 1984).
Rodenbaugh, D.W. et al. Parvalbumin isoforms differentially accelerate cardiac myocyte relaxation kinetics in an animal model of diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 293, H1705–H1713 (2007).
Harrison, S.M. & Bers, D.M. Modification of temperature dependence of myofilament Ca sensitivity by troponin C replacement. Am. J. Physiol. 258, C282–C288 (1990).
McKillop, D.F. & Geeves, M.A. Regulation of the interaction between actin and myosin subfragment 1: evidence for three states of the thin filament. Biophys. J. 65, 693–701 (1993).
Takeda, S., Yamashita, A., Maeda, K. & Maeda, Y. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature 424, 35–41 (2003).
Hoffmann, B., Schmidt-Traub, H., Perrot, A., Osterziel, K.J. & Gessner, R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum. Mutat. 17, 524 (2001).
Schmidtmann, A. et al. Cardiac troponin C–L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C. FEBS J. 272, 6087–6097 (2005).
Baryshnikova, O.K., Li, M.X. & Sykes, B.D. Modulation of cardiac troponin C function by the cardiac-specific N-terminus of troponin I: influence of PKA phosphorylation and involvement in cardiomyopathies. J. Mol. Biol. 375, 735–751 (2008).
Dzimiri, N. Regulation of β-adrenoceptor signaling in cardiac function and disease. Pharmacol. Rev. 51, 465–501 (1999).
Bristow, M.R. et al. Decreased catecholamine sensitivity and β-adrenergic–receptor density in failing human hearts. N. Engl. J. Med. 307, 205–211 (1982).
Townsend, D. et al. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086–1092 (2007).
Andersson, K.B. et al. Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J. Mol. Cell Cardiol. 47, 180–187 (2009).
Mogensen, J. et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111, 209–216 (2003).
Davis, J., Wen, H., Edwards, T. & Metzger, J.M. Thin filament disinhibition by restrictive cardiomyopathy mutant R193H troponin I induces Ca2+-independent mechanical tone and acute myocyte remodeling. Circ. Res. 100, 1494–1502 (2007).
Davis, J. et al. Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy. J. Mol. Cell Cardiol. 53, 446–457 (2012).
Kawasaki, H. & Kretsinger, R.H. Calcium-binding proteins 1: EF-hands. Protein Profile 2, 297–490 (1995).
Marsden, B.J., Shaw, G.S. & Sykes, B.D. Calcium binding proteins. Elucidating the contributions to calcium affinity from an analysis of species variants and peptide fragments. Biochem. Cell Biol. 68, 587–601 (1990).
Kitzman, D.W. & Daniel, K.R. Diastolic heart failure in the elderly. Heart Fail. Clin. 3, 437–453 (2007).
Lorell, B.H. Significance of diastolic dysfunction of the heart. Annu. Rev. Med. 42, 411–436 (1991).
Mann, D.L. Heart Failure: A Companion to Braunwald's Heart Disease. Chap. 7 (Elsevier Health Sciences, 2004).
Tang, W.H. & Francis, G.S. The year in heart failure. J. Am. Coll Cardiol. 52, 1671–1678 (2008).
Ingwall, J.S. & Weiss, R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 95, 135–145 (2004).
Westfall, M.V., Rust, E.M., Albayya, F. & Metzger, J.M. Adenovirus-mediated myofilament gene transfer into adult cardiac myocytes. Methods Cell Biol. 52, 307–322 (1997).
Potter, J.D., Strang-Brown, P., Walker, P.L. & Iida, S. Ca2+ binding to calmodulin. Methods Enzymol. 102, 135–143 (1983).
Guan, K.L. & Dixon, J.E. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192, 262–267 (1991).
Tikunova, S.B. & Davis, J.P. Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C. J. Biol. Chem. 279, 35341–35352 (2004).
Coutu, P. & Metzger, J.M. Genetic manipulation of calcium-handling proteins in cardiac myocytes. I. Experimental studies. Am. J. Physiol. Heart Circ. Physiol. 288, H601–H612 (2005).
Masuda, H. & de Meis, L. Effect of temperature on the Ca2+ transport ATPase of sarcoplasmic reticulum. J. Biol. Chem. 252, 8567–8571 (1977).
Puglisi, J.L., Bassani, R.A., Bassani, J.W., Amin, J.N. & Bers, D.M. Temperature and relative contributions of Ca transport systems in cardiac myocyte relaxation. Am. J. Physiol. 270, H1772–H1778 (1996).
Stein, R.B., Gordon, T. & Shriver, J. Temperature dependence of mammalian muscle contractions and ATPase activities. Biophys. J. 40, 97–107 (1982).
Hou, T.T., Johnson, J.D. & Rall, J.A. Effect of temperature on relaxation rate and Ca2+, Mg2+ dissociation rates from parvalbumin of frog muscle fibres. J. Physiol. (Lond.) 449, 399–410 (1992).
Herron, T.J. et al. Calcium-independent negative inotropy by β-myosin heavy chain gene transfer in cardiac myocytes. Circ. Res. 100, 1182–1190 (2007).
Tocchetti, C.G. et al. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ. Res. 100, 96–104 (2007).
Metzger, J.M. Myosin binding–induced cooperative activation of the thin filament in cardiac myocytes and skeletal muscle fibers. Biophys. J. 68, 1430–1442 (1995).
Herron, T.J. et al. Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by α-myosin motor gene transfer. FASEB J. 24, 415–424 (2010).
Maddaford, T.G., Hurtado, C., Sobrattee, S., Czubryt, M.P. & Pierce, G.N. A model of low-flow ischemia and reperfusion in single, beating adult cardiomyocytes. Am. J. Physiol. 277, H788–H798 (1999).
Day, S.M. et al. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat. Med. 12, 181–189 (2006).
We thank T. Herron, E. Devaney, I. Turner, M. Maerz, F. Sjaastad, B. Liu, S. Little and T. Edwards for their assistance. We thank the Lillehei Heart Institute for support. We thank H. Sabbah (Henry Ford Hospital Heart and Vascular Institute) for providing the canine failing myocytes. We thank K.B. Andersson and G. Christensen (Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway) for providing the mice with inducible cardiac myocyte–specific excision of the SERCA2a. This work was supported by the US National Institutes of Health (J.M.M. and J.D.P.).
The authors declare no competing financial interests.
About this article
Cite this article
Wang, W., Barnabei, M., Asp, M. et al. Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance. Nat Med 19, 305–312 (2013). https://doi.org/10.1038/nm.3079
This article is cited by
Nature Communications (2022)
Ophiopogonin D maintains Ca2+ homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3/EETs and suppressing ER stress
Acta Pharmacologica Sinica (2016)